Compare VMD & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | VMD | CTNM |
|---|---|---|
| Founded | 2006 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 465.4M | 550.7M |
| IPO Year | 2018 | 2024 |
| Metric | VMD | CTNM |
|---|---|---|
| Price | $9.20 | $14.19 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 396.6K | 323.2K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.14 | 0.46 |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $270,280,000.00 | N/A |
| Revenue This Year | $17.88 | N/A |
| Revenue Next Year | $14.98 | N/A |
| P/E Ratio | $70.54 | ★ N/A |
| Revenue Growth | ★ 20.52 | N/A |
| 52 Week Low | $6.05 | $7.26 |
| 52 Week High | $12.61 | $16.91 |
| Indicator | VMD | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 23.46 | 47.45 |
| Support Level | $8.03 | $13.23 |
| Resistance Level | $10.05 | $15.69 |
| Average True Range (ATR) | 0.43 | 1.19 |
| MACD | -0.24 | -0.09 |
| Stochastic Oscillator | 1.52 | 34.01 |
Viemed Healthcare Inc is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women's health products and services. The Company's primary service offerings focus on effective in-home treatment, with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. The company generates the majority of its revenue from medical equipment rental, sales, and supply.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.